Food and Drug Administration’s approval hands drugmaker Novo Nordisk an edge in the race to market an obesity pill

The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own obesity pill.

It marks a first in this new era of weight-loss medications with Wegovy being the only so far to gain approval for a pill version of their shot.